Molecular genetics of familial cutaneous melanoma

Journal of Clinical Oncology

Volumn 16, Issue 2, 1998, Pages 670-682

  Haluska, Frank G ^a   Hodi, F Stephen ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER GENETICS; CANCER RISK; CHROMOSOME 1; CHROMOSOME 9; GENE ISOLATION; HUMAN; MAJOR CLINICAL STUDY; MELANOMA; PRIORITY JOURNAL; SKIN CARCINOGENESIS;

EID: 0031894534     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.2.670     Document Type: Article

References (108)

1. Balch CM, Reintgen DS, Kirkwood JM, et al: Cutaneous melanoma, in DeVita VT Jr, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology. Philadelphia, PA, Lippincott-Raven, 1997, pp 1947-1994
2. Grin-Jorgensen CM, Rigel DS, Friedman RJ: The worldwide incidence of malignant melanoma, in Balch CM, Houghton AN, Milton GW, et al (eds): Cutaneous Melanoma (ed 2). Philadelphia, PA, Lippincott, 1992, pp 27-39
3. Parker SL, Tong T, Bolden S, et al: Cancer statistics, 1997. CA Cancer J Clin. 47:5-27, 1997
4. Armstrong BK, English DR: Epidemiologic studies, in Balch CM, Houghton AN, Milton GW, et al (eds): Cutaneous Melanoma (ed 2). Philadelphia, PA. Lippincott, 1992, pp 12-26
5. Cawley EP: Genetic aspects of malignant melanoma. Arch Dermatol Syphilis 65:440-450, 1952
6. Greene MH, Fraumeni JF Jr: The hereditary variant of malignant melanoma, in Clark WH Jr, Goldman LI, Mastrangelo MJ (eds): Human Malignant Melanoma. New York, NY, Grune Stratton, 1979, pp 139-166
7. Anderson DE: Clinical characteristics of the genetic variety of cutaneous melanoma in man. Cancer 28:721, 1971
8. Wallace DC, Beardmore GL, Exton LA: Familial malignant melanoma. Ann Surg 177:15, 1973
9. Duggleby WF, Stoll H, Priore RL, et al: A genetic analysis of melanoma-polygenic inheritance as a threshold trait. Am J Epidemiol 114:61-72, 1981
10. Clark WH Jr, Reimer RR, Greene M, et al: Origin of familial malignant melanomas from heritable melanocytic lesions: The B-K mole syndrome. Arch Dermatol 114:723-728, 1978
11. Lynch HT, Frichot BC III, Lynch JF: Familial atypical multiple mole-melanoma syndrome. J Med Genet 15:352-356, 1978
12. Crutcher WA, Sagebiel RW: Prevalence of dysplastic nevi in a community practice. Lancet 1:729, 1984
13. Piepkorn M, Meyer LJ, Goldgar D, et al: The dysplastic melanocytic nevus: A prevalent lesion that correlates poorly with clinical phenotype. J Am Acad Dermatol 20:407-415, 1989
14. Greene MH, Goldin LR, Clark WH Jr, et al: Familial cutaneous malignant melanoma: Autosomal dominant trait possibly linked to the Rh locus. Proc Natl Acad Sci USA 80:6071-6075, 1983
15. Bale SJ, Chakravarti A, Greene MH: Cutaneous malignant melanoma and familial dysplastic nevi: Evidence for autosomal dominance and pleiotropy. Amer J Hum Genet 38:188-196, 1986
16. Cannon-Albright L, Kamb A, Skolnick M: A review of inherited predisposition to melanoma. Semin Oncol 23:667-672, 1996
17. Fountain JW, Bale SJ, Housman DE, et al: Genetics of melanoma. Cancer Surv 9:645-671, 1990
18. Albino AP, Fountain JW: Molecular genetics of malignant melanoma, in Nathanson L (ed): Current Research and Clinical Management of Melanoma. Norwell, MA, Kluwer Academic, 1993, pp 201-255
19. Thompson FH, Emerson J, Oison S, et al: Cytogenetics of 158 patients with regional or disseminated melanoma. Cancer Genet Cytogenet 83:93-104, 1995
20. Dracopoli NC, Houghton AN, Old LJ: Loss of polymorphic restriction fragments in malignant melanoma: Implications for tumor heterogeneity. Proc Natl Acad Sci USA 82:1470-1474, 1985
21. Dracopoli NC, Harnett P, Bale SJ, et al: Loss of alleles from the distal short arm of chromosome 1 occurs late in melanoma tumor progression. Proc Natl Acad Sci USA 86:4614-4618, 1989
22. Dracopoli NC, Alhadeff B, Houghton AN, et al: Loss of heterozygosity at autosomal and X-linked loci during tumor progression in a patient with melanoma. Cancer Res 47:3995-4000, 1987
23. Fountain JW, Karayiorgou M, Ernstoff MS, et al: Homozygous deletions within human chromosome band 9p21 in melanoma. Proc Natl Acad Sci USA 89:10557-10561, 1992
24. Bale SJ, Dracopoli NC, Tucker MA: The genetics of human cutaneous malignant melanoma, in Balch CM, Houghton AN, Milton GW, et al (eds): Cutaneous Melanoma. Philadelphia, PA, Lippincott, 1992, pp 93-100
25. Dracopoli NC, Stanger BZ, Ito CY, et al: A genetic linkage map of 27 loci from PND to FY on the short arm of human chromosome 1. Amer J Hum Genet 43:462-470, 1988
26. Bale SJ, Dracopoli NC, Tucker MA, et al: Mapping the gene for hereditary cutaneous malignant melanoma-dysplastic nevus syndrome to chromosome 1p. N Engl J Med 320:1367-1372, 1989
27. van Haeringen A, Bergman W, Nelen MR, et al: Exclusion of the dysplastic naevus syndrome (DNS) from the short arm of chromosome 1 by linkage studies in Dutch families. Genomics 5:61-64, 1989
28. Cannon-Albright LA, Goldgar DE, Wright EC, et al: Evidence against the reported linkage of the cutaneous melanoma-dysplastic nevus syndrome locus to chromosome 1p36. Amer J Hum Genet 46:912-918, 1990
29. Gruis NA, Bergman W, Fronts RR: Locus for susceptibility to melanoma on chromosome 1p. N Engl J Med 322:853-854, 1990
30. Kefford RF, Salmon J, Shaw HM, et al: Hereditary melanoma in Australia: Variable association with dysplastic nevi and absence of genetic linkage to chromosome 1p. Cancer Genet Cytogenet 51:45-55, 1991
31. Nancarrow DJ, Palmer JM, Walters MK, et al: Exclusion of the familial melanoma locus (MLM) from the PND/D1S47 and MYCL1 regions of chromosome arm 1p in 7 Australian pedigrees. Genomics 12:18-25, 1992
32. Goldstein AM, Dracopoli NC, Ho EC, et al: Further evidence for a locus for cutaneous malignant melanoma-dysplastic nevus (CMM/DN) on chromosome 1p, and evidence for genetic heterogeneity. Amer J Hum Genet 52:537-550, 1993
33. Goldstein AM, Dracopoli NC, Engelstein M, et al: Linkage of cutaneous malignant melanoma/dysplastic nevi to chromosome 9p, and evidence for genetic heterogeneity. Amer J Hum Genet 54:489-496, 1994
34. Goldstein AM, Goldin LR, Dracopoli NC, et al: Two-locus linkage analysis of cutaneous malignant melanoma/dysplastic nevi. Am J Hum Genet 58:1050-1056, 1996
35. Cannon-Albright LA, Goldgar DE, Meyer LJ, et al: Assignment of a locus for familial melanoma. MLM, to chromosome 9p13-p22. Science 258:1148-1152, 1992
36. Nancarrow DJ, Mann GJ, Holland EA, et al: Confirmation of chromosome 9p linkage in familial melanoma. Amer J Hum Genet 53:936-942, 1993
37. Gruis NA, Sandkuijl LA, Weber JL: Linkage analysis in Dutch familial atypical multiple mole-melanoma (FAMMM) syndrome families. Effect of nevus count. Melanoma Res 3:271-277, 1993
38. Haluska FG, Housman DE: Recent advances in the molecular genetics of malignant melanoma, in Ponder BAJ, Cavenee WK, Solomon E (eds): Genetics and Cancer: A Second Look. Cancer Surveys. Cold Spring Harbor, Cold Spring Harbor Laboratory Press, 1995, pp 277-292
39. Kamb A, Gruis N, Weaver-Feldhaus J, et al: A cell cycle regulator potentially involved in genesis of many tumor types. Science 264:436-440, 1994
40. Nobori T, Miura K, Wu DJ, et al: Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368:753-756, 1994
41. Hunter T, Pines J: Cyclins and cancer II: Cyclin D and CDK inhibitors come of age. Cell 79:573-582, 1994
42. Xiong Y, Zhang H, Beach D: Subunit rearrangement of the cyclin-dependent kinases is associated with cellular transformation. Genes Devel 7:1572-1583, 1993
43. Serrano M, Hannon GJ, Beach D: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK 4. Nature 366:704-707, 1993
44. Hannon GJ, Beach D: p15 INK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature 371:257-261, 1994
45. INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes Devel 8:2939-2952, 1994
46. INK4a transcript. Cancer Res 55:2995-2997, 1995
47. Stone S, Jiang P, Dayananth P, et al: Complex structure and regulation of the p16(MTS1) locus. Cancer Res. 55:2988-2994, 1995
48. Quelle DE, Zindy F, Ashmun RA, et al: Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83:993-1000, 1995
49. Okamoto A, Demetrick DJ, Spillare EA, et al: Mutations and altered expression of p16INK4 in human cancer. Proc Natl Acad Sci USA 91:11045-11049, 1994
50. Cairns P, Mao L, Merlo A, et al: Rates of p16(MTS1) mutations in primary tumors with 9p loss. Science 265:415-416, 1994
51. Pollock PM, Pearson JV, Hayward NK: Compilation of somatic mutations of the CDKN2 gene in human cancers: Non-random distribution of base substitutions. Genes Chromosom Cancer 15:77-88, 1996
52. Smith-Sorenson B, Hovig E: CDKN2A (P16(INK4A)) somatic and germline mutations. Hum Mutat 7:294-303, 1996
53. Foulkes WD, Flanders TY, Pollock PM, et al: The CDKN2A (p16) gene and human cancer. Molec Med 3:5-20, 1997
54. INK4b genes, as well as neighboring 9p21 markers, in sporadic melanoma. Cancer Res 56:5023-5032, 1996
55. Merlo A, Herman J, Mao L, et al: 5′ CpG island methylation is associated with inactivation of the tumor suppressor CDKN2/p16 in human tumors. Nature Med 1:686-692, 1995
56. INK4 protein induction by 5-aza 2′deoxycytidine. Oncogene 11:1211-1216, 1995
57. Herman JG, Merlo A, Mao L, et al: Inactivation of the CDKN2/p16MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 55:4525-4530, 1995
58. Gonzalez-Zulueta M, Bender CM, Yang AS, et al: Methylation of the 5′ CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res 55:4531-4535, 1995
59. Costello JF, Berger MS, Huang H-JS, et al: Silencing of p16/CDKN2 expression in human gliomas by methylation and chromatin condensation. Cancer Res 56:2405-2410, 1996
60. Lo K-W, Cheung S-T, Leung S-F, et al: Hypermethylation of the p16 gene in nasopharyngeal carcinoma. Cancer Res 56:2721-2725, 1996
61. Batova A, Diccianni MB, Yu JC, et al: Frequent and selective methylation of p15 and deletion of both p15 and p16 in T-cell acute lymphoblastic leukemia. Cancer Res 57:832-836, 1997
62. Takita J, Hayashi Y, Kohno T, et al: Deletion map of chromosome 9 and p16(CDKN2A) gene alterations in neuroblastoma. Cancer Res 57:907-912, 1997
63. Hussussian CJ, Struewing JP, Goldstein AM, et al: Germline p16 mutations in familial melanoma. Nature Genet 8:15-21, 1994
64. Kamb A, Shattuck-Eidens D, Eelens R, et al: Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nature Genet 8:22-26, 1994
65. Gruis NA, van der Velden PA, Sandkuijl LA, et al: Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds. Nature Genet 10:351-353, 1995
66. Bressac-de Paillerets B, Soufir N, Chompret A, et al: Germ-line mutations in p16 and CDK4 genes in 38 melanoma families. Melanoma Res 7:S132, 1997 (supp. 1)
67. Lynch HT, Fusaro RM, Pester J, et al: Tumour spectrum in the FAMMM syndrome. Br J Cancer 44:553-560, 1981
68. Bergman W, Watson P, de Jong J, et al: Systemic cancer and the FAMMM syndrome. Br J Cancer 61:932-936, 1990
69. Kopf AW, Hellman LJ, Rogers GS, et al: Familial malignant melanoma. JAMA 256:1915-1919, 1986
70. Swerdlow AJ, Storm HH, Sasieni PD: Risks of second primary malignancy in patients with cutaneous and ocular melanoma. Int J Cancer 61:773-779, 1995
71. Caldas C, Hahn S, da Costa L et al: Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nature Genet 8:27-32, 1994
72. INK4 mutations. N Engl J Med 333:970-974, 1995
73. Whelan AJ, Bartsch D, Goodfellow PJ: Brief report: A familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor suppressor gene. N Engl J Med 333:975-977, 1995
74. Ciotti P, Strigini P, Bianchi-Scarra G: Familial melanoma and pancreatic cancer. N Engl J Med 334:469-470, 1996
75. INK4a allele. J Natl Cancer Inst 88:1489-1491, 1996
76. Zhang S-Y, Klein-Szanto AJP, Sauter ER, et al: Higher frequency of alterations in the p16/CDKN2 gene in squamous cell carcinoma cell lines than in primary tumors of the head and neck. Cancer Res 54:5050-5053, 1994
77. Mori T, Koh M, Aoki T, et al: Frequent somatic mutations of the MTS1/CDK41 (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma. Cancer Res 54:3396-3397, 1994
78. Draper GJ, Sanders BM, Kingston JE: Second primary neoplasms in patients with retinoblastoma. Br J Cancer 53:661-671, 1986
79. DerKinderen DJ, Koten JW, Nagelkerke NJD, et al: Non-ocular cancer in patients with hereditary retinoblastoma and their relatives. Int J Cancer 41:499-504, 1988
80. Eng C, Li FP, Abramson DH, et al: Mortality from second tumors among long-term survivors of retinoblastoma. J Natl Cancer Inst 85:1121-1129, 1993
81. Bataille V, Hiles R, Bishop JAN: Retinoblastoma, melanoma and the atypical mole syndrome. Br J Dermatol 132:134-138, 1995
82. Horowitz JM, Park S-H, Bogenmann E, et al: Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumor cells. Proc Natl Acad Sci USA 87:2775-2779, 1990
83. Maelandsmo GM, Florenes VA, Hovig E, et al: Involvement of the pRb/p16/cdk4/cyclinD1 pathway in the tumorigenesis of sporadic malignant melanomas. Br J Cancer 73:909-916, 1996
84. Kawakami Y, Robbins PF, Wang RF, et al: Identification of melanoma antigens recognized by T lymphocytes and their use in the immunotherapy of cancer. PPO Updates 10:1-20, 1996
85. INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269:1281-1284, 1995
86. Bartkova J, Lukas J, Guldberg P, et al: The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis. Cancer Res 56:5475-5483, 1996
87. Piccinin S, Doglioni C, Maestro R, et al: p16/CDKN2 and CDK4 gene mutations in sporadic melanoma development and progression. Int J Cancer 74:26-30, 1997
88. INK4a binding domain of CDK4 in familial melanoma. Nature Genet 12:97-99, 1996
89. FitzGerald MG, Harkin DP, Silva-Arrieta S, et al: Prevalence of germ-line mutations in p16, p19ARF, and CDK4: Analysis of a clinic-based population. Proc Natl Acad Sci USA 93:8541-8545, 1996
90. Hayward N, Flores J, Pollock P, et al: Analysis of the CDKN2A, CDKN2B and CDK4 genes in 48 Australian melanoma kindreds. Melanoma Res 7 S37, 1997 (supp 1)
91. Holland EA, Becker TM, Kefford RF, et al: Mutation analysis of CDKN2A and CDK4 in familial melanoma. Melanoma Res 7 S133, 1997 (supp 1)
92. Platz A, Hansson J, Mansson-Brahme E, et al: Population based screening of germline mutations in the CDKN2A, CDKN2B, CDK4 and p53 genes in Swedish families with hereditary cutaneous melanoma. Melanoma Res 7 S37, 1997 (supp. 1)
93. Tucker MA, Halpern A, Holly EA, et al: Clinically recognized dysplastic nevi: A central risk factor for cutaneous melanoma. JAMA 277:1439-1444, 1997
94. Chabner BA, Haluska FG, Talcott JA: Screening strategies for cancer: Implications and results. JAMA 277:1475-1476, 1997
95. Platz A, Hansson J, Mansson-Brahme E, et al: Screening of germline mutations in the CDKN2A and CDKN2B genes in Swedish families with hereditary cutaneous melanoma. J Natl Cancer Inst 89:697-702, 1997
96. Cannon-Albright L, Meyer LJ, Goldgar DE, et al: Penetrance and expressivity of the chromosome 9p susceptibility locus. Cancer Res 54:6041-6044, 1994
97. Walker GJ, Hussussian CJ, Flores JF, et al: Mutations of the CDKN2/p16INK4 gene in Australian melanoma kindreds. Hum Molec Genet 4:1845-1852, 1995
98. American SoCO: Statement of the American Society of Clinical Oncology: Genetic testing for cancer susceptibility. J Clin Oncol 14:1730-1736, 1996
99. Gruis NA, Weaver-Feldhaus J, Liu Q, et al: Genetic evidence in melanoma and bladder cancers that p16 and p53 function in separate pathways of tumor suppression. Amer J Pathol 146:1199-1207, 1995
100. Liu Q, Neuhausen S, McClure M, et al: CDKN2 (MTS1) tumor suppressor gene mutations in human tumor cell lines. Oncogene 10:1061-1067, 1995
101. Ohta M, Nagai H, Shimizu M, et al: Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene. CDK4I, in melanoma. Cancer Res 54:5269-5272, 1994
102. Pollock PM, Yu F, Qiu L, et al: Evidence for u.v. induction of CDKN2 mutations in melanoma cell lines. Oncogene 11:663-668, 1995
103. INK4/MTS-1) gene in human melanoma cells: Relevance to tumor growth and metastasis. Oncogene 11:1399-1402, 1995
104. Platz A, Ringborg U, Lagerlof B, et al: Mutational analysis of the CDKN2 gene in metastasis from patients with cutaneous malignant melanoma. Br J Cancer 73:344-348, 1996
105. INK4 in sporadic melanoma. J Invest Dermatol 107:318-321, 1996
106. Liu L, Lassam NJ, Slingerland JM, et al: Germline p16INK4A mutation and protein dysfunction in a family with inherited melanoma. Oncogene 11:405-412, 1995
107. Holland EA, Beaton SC, Becker TM, et al: Analysis of the p16 gene, CDKN2, in 17 Australian melanoma kindreds. Oncogene 11:2289-2294, 1995
108. Borg A, Johansson U, Johannsson O, et al: Novel germline p16 mutation in familial malignant melanoma in southern Sweden. Cancer Res 56:2497-2500, 1996